KAT2B and CCNA2

Data Source:
BioGRID (enzymatic study)

		KAT2B	CCNA2
Description		lysine acetyltransferase 2B	cyclin A2
Image
GO Annotations	Cellular Component	PCAF Complex Kinetochore Nucleus Nucleoplasm Ada2/Gcn5/Ada3 Transcription Activator Complex Centrosome Cytosol A Band I Band Protein-containing Complex Actomyosin	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex
	Molecular Function	RNA Polymerase II Transcription Regulatory Region Sequence-specific DNA Binding Chromatin Binding Transcription Coregulator Activity Transcription Coactivator Activity Diamine N-acetyltransferase Activity Histone Acetyltransferase Activity Lysine N-acetyltransferase Activity, Acting On Acetyl Phosphate As Donor Cyclin-dependent Protein Serine/threonine Kinase Inhibitor Activity Protein Binding Transcription Factor Binding Acetyltransferase Activity Protein Kinase Binding Histone Deacetylase Binding Peptide-lysine-N-acetyltransferase Activity	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding
	Biological Process	Chromatin Remodeling Transcription Initiation From RNA Polymerase II Promoter Protein Acetylation Cell Cycle Arrest Notch Signaling Pathway Positive Regulation Of Transcription Of Notch Receptor Target Heart Development Negative Regulation Of Cell Population Proliferation Regulation Of Protein ADP-ribosylation Viral Process Protein Deubiquitination N-terminal Peptidyl-lysine Acetylation Protein Phosphopantetheinylation Internal Peptidyl-lysine Acetylation Peptidyl-lysine Acetylation Cellular Response To Insulin Stimulus Histone H3 Acetylation Histone H3-K9 Acetylation Regulation Of Megakaryocyte Differentiation Positive Regulation Of Gluconeogenesis Negative Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity Positive Regulation Of Notch Signaling Pathway Positive Regulation Of Gene Expression, Epigenetic Positive Regulation Of Transcription By RNA Polymerase II Negative Regulation Of Centriole Replication Rhythmic Process Limb Development Negative Regulation Of RRNA Processing	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Viral Process Histone Phosphorylation Protein Deubiquitination Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus
Pathways		Pre-NOTCH Transcription and Translation Pre-NOTCH Transcription and Translation YAP1- and WWTR1 (TAZ)-stimulated gene expression Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells NOTCH1 Intracellular Domain Regulates Transcription NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HATs acetylate histones Notch-HLH transcription pathway B-WICH complex positively regulates rRNA expression Physiological factors Metalloprotease DUBs RNA Polymerase I Transcription Initiation RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX3 regulates NOTCH signaling RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription Estrogen-dependent gene expression Regulation of FOXO transcriptional activity by acetylation	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry
Drugs		Coenzyme A (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE N-(3-AMINOPROPYL)-2-NITROBENZENAMINE	4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Drug abuse ( 26202629) High light scatter reticulocyte count ( 32888494) Mean arterial pressure (alcohol consumption interaction) ( 24376456) Mean corpuscular hemoglobin ( 32888494 27863252) Mean corpuscular volume ( 29403010 32888494 27863252) Mean reticulocyte volume ( 32888494) Mean spheric corpuscular volume ( 32888494) Optic disc size ( 31809533) Post-traumatic stress disorder ( 24677629) Red blood cell count ( 32888494) Reticulocyte count ( 32888494) Reticulocyte fraction of red cells ( 32888494) Staphylococcus aureus nasal carriage (intermittent) ( 26569114) Systolic blood pressure ( 30224653 30578418)	Mean corpuscular hemoglobin ( 32888494)
Interacting Genes		121 interacting genes: ACTN1 ACTN2 AKT1 AR ARHGDIA ARNTL ATF4 ATXN3 BRCA2 CCNA2 CCND1 CCNT1 CDC25B CDCA4 CDK2 CDKN1B CDT1 CEBPB CEP250 CIITA CLOCK CREBBP CTBP1 CTNNB1 CUX1 DACH2 DEK EP300 ESRRA ETV1 EZH2 GATAD2A GATAD2B H1-1 H1-5 H2AC20 H2AC4 H2BC21 H2BC3 H3-3A H3-4 H3C1 H3C14 H4-16 H4C1 HIPK2 HMGA1 HMGN2 HNF1A HNRNPU HOXB9 HSD11B2 HTT ING1 IRF1 IRF2 IRF7 JDP2 KLF10 KLF13 KLF2 LIN28B MAPK14 MAPRE1 MDM2 MECOM MYC MYOD1 NCOA1 NCOA3 NCOA4 NFATC1 NFE2 NFE4 NOTCH1 NOTCH3 NPAS2 NR1H3 NR4A1 NRIP1 ONECUT1 PARP1 PDK1 PGR PLAGL1 PNMA1 POLR2A PTF1A RAB11A RARA RB1 RBM8A RBPJ RELA RPS6KB1 RPS6KB2 SAT2 SATB1 SERBP1 SERTAD1 SERTAD2 SIRT2 SMAD1 SMAD2 SMAD3 SRCAP TACC2 TAL1 TCF3 TMF1 TP53 TP63 TP73 TRIM14 TTF1 TWIST1 UBE2D1 UBE2D2 UBE2D3 XRCC6 YY1	49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBE2C UBTF USP37
Entrez ID		8850	890
HPRD ID		06780	00453
Ensembl ID		ENSG00000114166	ENSG00000145386
Uniprot IDs		Q92831	P20248
PDB IDs		1CM0 1JM4 1N72 1WUG 1WUM 1ZS5 2RNW 2RNX 3GG3 4NSQ 5FDZ 5FE0 5FE1 5FE2 5FE3 5FE4 5FE5 5FE6 5FE7 5FE8 5FE9 5LVQ 5LVR 5MKX 6J3O	1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?